What FDA approval actually provides — and what gray-market sourcing doesn't

Full analysis

Peter Attia argues that FDA approval should be understood not as infallibility but as an information package: a defined benefit in a defined population, a studied dose and route of administration, a characterized safety profile with known drug interactions, and manufacturing standards for identity, potency, purity, and lot-to-lot consistency. None of that information is created by a physician's prescription, a compounding pharmacy, or a third-party purity test. A doctor's involvement may improve screening and injection technique but does not validate the dose or prove the product matches the studied pharmaceutical. Third-party testing by analytical methods such as HPLC or mass spectrometry can confirm a molecule's identity and approximate concentration but cannot assess sterility or batch-to-batch consistency. He also cautions that even when a gray-market peptide claims to contain the same amino acid sequence as an approved drug, the clinical trial evidence belongs to a specific manufactured product — not to any preparation sharing that sequence — because manufacturing processes affect a drug's pharmacological properties.